Medivir Logo

Medivir

Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.

MVIR | ST

Overview

Corporate Details

ISIN(s):
SE0000325151 (+4 more)
LEI:
549300VWDGUX0WMJ1T79
Country:
Sweden
Address:
Box 1086, 141 22 Huddinge
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Medivir is a clinical-stage pharmaceutical company focused on developing innovative treatments for cancer. The company concentrates its research and development on oncology, specifically targeting cancers with high unmet medical needs where patients have few therapeutic options. Medivir's business strategy relies heavily on collaborations with academic and industrial partners to leverage specialized knowledge and advance its projects. Through this partnership-driven approach, the company has previously succeeded in taking products from research through clinical development to global launch. Its pipeline includes the development of novel tumor-directed therapies such as oral prodrugs.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-08 09:15
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Medivir AB (publ)
Swedish 80.7 KB
2025-10-08 09:15
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting of Medivir AB (publ)
English 82.0 KB
2025-10-08 08:52
Share Issue/Capital Change
Medivir beslutar om en fullt garanterad företrädesemission motsvarande cirka 15…
Swedish 81.6 KB
2025-10-08 08:52
Share Issue/Capital Change
Medivir announces a fully guaranteed rights issue of approximately SEK 151 mill…
English 81.3 KB
2025-08-21 08:30
Interim Report
Swedish 392.4 KB
2025-08-21 08:30
Interim Report
English 331.5 KB
2025-05-07 15:30
Post-Annual General Meeting Information
Resolutions at the Annual General Meeting in Medivir on 7 May 2025
English 40.6 KB
2025-05-07 15:30
Post-Annual General Meeting Information
Beslut vid årsstämma i Medivir den 7 maj 2025
Swedish 40.8 KB
2025-04-29 08:30
Quarterly Report
Swedish 395.9 KB
2025-04-29 08:30
Interim Report
English 337.0 KB
2025-02-25 11:24
Major Shareholding Notification
Swedish 9.1 KB
2025-02-18 08:30
Annual Report
Swedish 410.1 KB
2025-02-18 08:30
Earnings Release
English 339.3 KB
2025-02-03 10:37
Major Shareholding Notification
Swedish 9.1 KB
2025-02-01 11:01
Major Shareholding Notification
Swedish 8.9 KB

Automate Your Workflow. Get a real-time feed of all Medivir filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Medivir via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2022-11-15 Fredrik Öberg Other Buy 100,000 77,000.00 SEK
2022-11-14 Jens Anders Fredrik Lindberg Other Buy 250,000 192,500.00 SEK
2022-11-14 Magnus Christensen Other Buy 150,000 115,500.00 SEK
2022-03-28 Jens Anders Fredrik Lindberg Other Buy 15,000 122,850.00 SEK
2022-03-25 Jens Anders Fredrik Lindberg Other Buy 10,000 80,000.00 SEK
2022-03-03 Magnus Christensen Other Buy 6,000 46,800.00 SEK
2021-12-23 Malene Jensen Other Buy 15,000 25,650.00 SEK
2021-12-13 Malene Jensen Other Buy 50,000 109,500.00 SEK
2021-12-13 Malene Jensen Other Buy 50,000 85,500.00 SEK
2021-05-13 Fredrik Öberg Other Buy 97,500 97,500.00 SEK

Peer Companies

Company Country Ticker View
FARON PHARMACEUTICALS OY Logo
Develops myeloid cell-targeting immunotherapies for solid and hematological cancers.
Finland FARN
Fluicell AB Logo
Developing bioprinted tissues for regenerative medicine and advanced drug screening.
Sweden FLUI
FluoGuide A/S Logo
Develops fluorescent drugs to guide surgeons for more precise cancer removal and patient outcomes.
Denmark FLUO
FUSION ANTIBODIES PLC Logo
A CRO providing end-to-end antibody engineering services for therapeutic & diagnostic development.
United Kingdom FAB
FUTURA MEDICAL PLC Logo
Develops topical sexual health gels, including a fast-acting, over-the-counter ED treatment.
United Kingdom FUM
GENINCODE PLC Logo
AI-powered genetic tests for physicians, predicting and preventing cardiovascular disease.
United Kingdom GENI
Genomic Vision Logo
Develops DNA analysis tools using Molecular Combing for genetic research and diagnostics.
France GV
Genxone Spolka Akcyjna Logo
A biotech firm offering nanopore DNA/RNA sequencing services and medical diagnostics.
Poland GX1
Hamlet BioPharma AB Logo
Developing selective therapies for cancer and infections like bladder cancer and UTIs.
Sweden HAMLET
Hipower Energy Spolka Akcyjna Logo
Develops hydrogen solutions, mobile refueling, and CO2-to-methanol tech for energy markets.
Poland HPE

Talk to a Data Expert

Have a question? We'll get back to you promptly.